Verinurad is a Small Molecule owned by AstraZeneca, and is involved in 20 clinical trials, which were completed.

Verinurad specifically binds to and inhibits URAT1, which is responsible for the regulation of uric acid levels in kidney. URAT1 mediates the reabsorption of uric acid, thereby regulating blood uric acid concentrations. The drug candidate inhibits the re-absorption of uric acid at the proximal convoluted tubule by facilitating urinary excretion of uric acid and decreasing plasma urate concentrations which is done through inhibition of the urate anion transporter.

The revenue for Verinurad is expected to reach a total of $91m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Verinurad NPV Report.

Verinurad was originated by Ardea Biosciences and is currently owned by AstraZeneca.

Verinurad Overview

Verinurad (RDEA-3170) is under development for the treatment of chronic kidney disease with preserved ejection fraction and hyperuricemia. It is administered by orally as a capsule. It is a next-generation inhibitor of the URAT1 transporter. It was under development for gout and hyperuricaemia, heart failure. It is a new molecular entity (NME).

AstraZeneca Overview

AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

The company reported revenues of (US Dollars) US$37,417 million for the fiscal year ended December 2021 (FY2021), an increase of 40.6% over FY2020. In FY2021, the company’s operating margin was 2.8%, compared to an operating margin of 19.4% in FY2020. In FY2021, the company recorded a net margin of 0.3%, compared to a net margin of 12% in FY2020. The company reported revenues of US$10,982 million for the third quarter ended September 2022, an increase of 2% over the previous quarter.

Quick View – Verinurad

Report Segments
  • Innovator
Drug Name
  • Verinurad
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Genito Urinary System And Sex Hormones
  • Metabolic Disorders
  • Musculoskeletal Disorders
Key Companies
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.